argenx SE | Investor Day Presentation Deck

Slide schematic 5/5

diagram 1/1 list 2/2 metric 1/1 title 1/1

Components 5

process bullet bullet big-number headline

Tools 1

The slide presents a clear Situation (study population and design), Complication (need for new treatments), Question (can Efgartigimod be effective?), and Answer (registrational study to start in 2021).

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

clinical-trial-design 90%

Standardized representation of patient population, intervention, and endpoints.

Find anything

Clinical trial design diagram showing a 1:1 randomization between Efgartigimod and Placebo over 36 weeks.